Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CDA | P32320 | 1/20 | 0.43 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.42 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.40 |
| ▸ | ADK | P55263 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16138515 | 1.00 | SLC5A2 (0.45) | SLC5A2LMNATHRBMTORMDM2 | |
| SCHEMBL16310914 | 1.00 | SLC5A2 (0.45) | SLC5A2LMNATHRBMTORMDM2 | |
| SCHEMBL19464856 | 1.00 | SLC5A2 (0.45) | SLC5A2LMNATHRBMTORMDM2 | |
| SCHEMBL19954920 | 1.00 | SLC5A2 (0.45) | SLC5A2LMNATHRBMTORMDM2 | |
| SCHEMBL15276437 | 1.00 | SLC5A2 (0.45) | SLC5A2LMNATHRBMTORMDM2 | |
| SCHEMBL15279674 | 1.00 | SLC5A2 (0.45) | SLC5A2LMNATHRBMTORMDM2 | |
| SCHEMBL19998418 | 0.87 | P2RY6 (0.53) | P2RY6 | |
| SCHEMBL20003779 | 0.87 | P2RY6 (0.53) | P2RY6 | |
| SCHEMBL16138506 | 0.86 | FEN1 (0.36) | SLC5A2LMNATHRBMTORMDM2 | |
| SCHEMBL15276383 | 0.84 | NT5E (0.53) | P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839615-B2 | Compounds and methods for treating addiction and related disorders | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20210030760-A1 | COMPOUNDS AND METHODS FOR TREATING ADDICTION AND RELATED DISORDERS | ASTROCYTE PHARMACEUTICALS, INC. | 2021-02-04 | — | — | US | disclosed |
| US-10265338-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180085386-A1 | URIDINE MONOPHOSPHATE AND TRIPHOSPHATE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY | 2018-03-29 | — | — | US | disclosed |
| US-20180021363-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10265338-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | SLC5A2 228/4885LMNA 573/4885THRB 2128/4885 |
| US-11839615-B2 | Compounds and methods for treating addiction and related disorders | ADORA2A, TAAR5, ADORA3 | SLC5A2 1169/4885LMNA 4573/4885THRB 872/4885 |
| US-20180085386-A1 | URIDINE MONOPHOSPHATE AND TRIPHOSPHATE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | P2RY6, UPP1, UMPS | SLC5A2 1656/4885LMNA 2136/4885THRB 1630/4885 |
| US-20180021363-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | SLC5A2 228/4885LMNA 573/4885THRB 2128/4885 |
| US-20210030760-A1 | COMPOUNDS AND METHODS FOR TREATING ADDICTION AND RELATED DISORDERS | SLC6A3, PNMT, CES2 | SLC5A2 902/4885LMNA 4444/4885THRB 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.